HNN3.0

CLUSTER Health Horizon Europe Brokerage Event 2027

24 – 25 Nov 2026

Register
Register
Register

Vector B2B - Drug Developing - Associação Para Investigação Em Biotecnologia

Company (SME)

vectorb2b.com/Lisbon, Portugal
2 profile visits

About

Your strategic partner in drug development – from discovery to clinical trials

At VectorB2B, we support companies throughout their R&D journey, combining scientific expertise with operational excellence.

**GUIDANCE FOR BIOTECHS
**We help design development programs, assess feasibility and navigate regulatory and quality requirements.

**PROGRAM MANAGMENT
**Our dedicated project managers act as your single point of contact, ensuring seamless planning and execution of development programs – from pre-clinical studies to clinical trials – with close study oversight.

**OUR EXPERTISE
**Pre-clinical:

  • Discovery

  • Toxicology

  • GLP Services

Clinical:

  • Medical Devices

  • Early Phase (I)

  • Late Phase (II – III)

  • Phase IV through to real-world evidence projects

**OPTIMIZED COSTS
**We deliver high-quality projects at competitive costs, leveraging our location to offer cost-effective solutions with predictable, fixed budgets tailored to your needs.

Representatives

Senior Project and Grant Manager

Vector B2B - Drug Developing - Associação Para Investigação Em Biotecnologia

Marketplace (1)

  • Project cooperation

    VectorB2B | Clinical Research, Hospital Access & European Funding Partner

    VectorB2B is a Portuguese CRO and SMO managing 50+ clinical studies, with hospital access to 650,000 patients. We support pre-clinical and clinical research, Horizon Europe proposals, consortium building and EU-funded project management.

    • Partner seeks Consortium/Coordinator
    • Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
    • Destination 5: HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine
    • Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
    • Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change
    • Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
    • Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
    • Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
    • Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
    • Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
    • Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
    • Destination 6: HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
    • Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
    • Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
    • Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
    • Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
    • Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
    • Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases

    Senior Project and Grant Manager at Vector B2B - Drug Developing - Associação Para Investigação Em Biotecnologia

    Lisbon, Portugal